SLU-PP-332 is a novel orally active small molecule being studied for its role as a selective REV-ERB agonist. This compound has gained attention in metabolic research for its ability to influence circadian rhythm pathways, mitochondrial biogenesis, and lipid metabolism—key targets in models of obesity, energy balance, and inflammatory states.
For research use only. Not for human consumption or therapeutic use.
Compound Details
- Form: Oral capsule
- Concentration: 100 mcg per capsule
- Capsules per bottle: 60
- Purity: >98% (HPLC-confirmed)
- Storage: Keep in a cool, dry environment away from light. Use within 12 months of opening for optimal stability.
Mechanism of Action
SLU-PP-332 acts as a synthetic agonist of the nuclear receptor REV-ERBα, a transcriptional repressor that regulates genes tied to:
- Circadian rhythm
- Inflammation pathways
- Mitochondrial respiration
- Lipid and glucose metabolism
Preclinical studies suggest that activation of REV-ERBα may suppress the expression of genes associated with fatty acid synthesis and inflammation, while enhancing genes involved in energy expenditure.
Areas of Research Focus
1. Metabolic Function Studies
SLU-PP-332 is commonly used in models examining:
- Obesity-related pathways
- Glucose homeostasis and insulin signaling
- Fatty acid oxidation and thermogenesis
2. Mitochondrial Biogenesis Models
By upregulating mitochondrial genes (e.g., CPT1B, UCP1), SLU-PP-332 is used to explore enhanced mitochondrial output and energy expenditure in skeletal muscle and liver models.
3. Circadian Biology
REV-ERB agonists have shown potential in aligning circadian rhythm gene expression, offering models to study sleep regulation, mood disorders, and shift-work-related metabolic dysregulation.
Compliance Statement
This compound is offered strictly for research and analytical purposes. It is not a dietary supplement, pharmaceutical, or nutraceutical. HVY Research does not support or promote its use in humans or animals.
There are no reviews yet.